Oppenheimer Asset Management Inc. Grows Stock Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Oppenheimer Asset Management Inc. boosted its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 10.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,712 shares of the company’s stock after purchasing an additional 6,260 shares during the period. Oppenheimer Asset Management Inc. owned about 0.91% of Global X Genomics & Biotechnology ETF worth $707,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. James J. Burns & Company LLC boosted its position in Global X Genomics & Biotechnology ETF by 35.6% in the fourth quarter. James J. Burns & Company LLC now owns 18,479 shares of the company’s stock worth $214,000 after purchasing an additional 4,848 shares during the last quarter. Centaurus Financial Inc. boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 14.6% in the fourth quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock worth $147,000 after buying an additional 1,624 shares during the last quarter. McGuire Investment Group LLC grew its position in Global X Genomics & Biotechnology ETF by 6.7% during the first quarter. McGuire Investment Group LLC now owns 58,651 shares of the company’s stock valued at $667,000 after buying an additional 3,696 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Global X Genomics & Biotechnology ETF by 16.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock worth $4,431,000 after acquiring an additional 53,178 shares during the period. Finally, Insight Advisors LLC PA purchased a new position in shares of Global X Genomics & Biotechnology ETF during the 1st quarter worth $152,000. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

NASDAQ:GNOM opened at $11.32 on Friday. Global X Genomics & Biotechnology ETF has a one year low of $8.63 and a one year high of $12.53. The business has a fifty day moving average price of $11.30 and a 200-day moving average price of $10.90. The firm has a market capitalization of $84.22 million, a price-to-earnings ratio of -4.85 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.